Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…Abstract Number: 2882 • 2019 ACR/ARP Annual Meeting
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated…Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…Abstract Number: 940 • 2019 ACR/ARP Annual Meeting
Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis
Background/Purpose: Most randomized controlled trials (RCTs) with biologic medicines in systemic lupus erythematosus (SLE) failed to reach their respective end-points with the rates of the…Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…Abstract Number: 1606 • 2019 ACR/ARP Annual Meeting
Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Background/Purpose: Smoking and African- American ethnicity are risk factors for systemic lupus erythematosus (SLE). Smoking has been associated with increased prevalence of SLE, increased disease…Abstract Number: 1767 • 2019 ACR/ARP Annual Meeting
Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease that causes progressive organ damage. The cytokines type I interferon (IFN-I), IL-12 and IL-23 have…Abstract Number: 2027 • 2019 ACR/ARP Annual Meeting
Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…Abstract Number: 2737 • 2019 ACR/ARP Annual Meeting
HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Background/Purpose: Hypoxia inducible factor 1 is a key transcription factor that regulates the cellular response to oxygen stress. In the adaptive immune system, HIF-1α is…Abstract Number: 2883 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria…
- « Previous Page
- 1
- …
- 139
- 140
- 141
- 142
- 143
- …
- 150
- Next Page »